Related Experiment Video
Updated: Oct 23, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes
H M Ockenfels1, G Nussbaum, T Schultewolter
1Department of Dermatology, University of Essen, Germany.
Abstract:
Protein tyrosine kinases (PTKs) are closely related to cell growth, proliferation and differentiation. In keratinocytes, various growth factor receptors and cytosolic proteins, including the EGF and IGF receptors, the proteins of the src family and others, exhibit PTK activity. In psoriatic epidermis an increased level of EGF receptors and their ligand TGF-alpha has been found, and this is thought to be one reason for the pathological hyperproliferation of keratinocytes in this disease. Oral treatment with cyclosporin A (CsA) and FK506 or topical treatment with dithranol lead to an improvement in psoriasis. In the present study we examined the effect of these three drugs on the cellular content of phosphorylated tyrosines in highly proliferative HaCaT keratinocytes. HaCaT keratinocytes can be used as a model for highly proliferative epidermis, e.g. psoriatic epidermis. CsA had no effect whereas FK506 and dithranol reduced the phosphorylation of tyrosine residues in HaCaT keratinocytes. The activation of serine/threonine protein kinase C (PKC) is known to downregulate PTKs. Therefore we incubated keratinocytes with the selective PKC inhibitor Ro 31-8220 in addition to the other drugs. Only after the addition of Ro 31-8220 to FK506-treated keratinocytes was the phosphotyrosine (p-tyr) level elevated, but this was only one-third of the increase measured without additional therapeutic drugs. We assume that an induction of PKC alone is not responsible for the reduced p-tyr level after treatment with dithranol and FK506.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
FK506 and dithranol reduce tyrosine phosphorylation in keratinocytes, potentially improving psoriasis. Cyclosporin A had no effect, and protein kinase C activation alone doesn't fully explain these drug effects.
Area of Science:
- Dermatology
- Biochemistry
- Cell Biology
Background:
- Protein tyrosine kinases (PTKs) regulate cell growth and differentiation.
- Abnormal PTK activity, particularly elevated EGF receptors, is linked to psoriatic hyperproliferation.
- Current treatments like cyclosporin A, FK506, and dithranol show efficacy in psoriasis.
Purpose of the Study:
- To investigate the impact of cyclosporin A, FK506, and dithranol on tyrosine phosphorylation in HaCaT keratinocytes.
- To explore the role of protein kinase C (PKC) in mediating the effects of these drugs.
Main Methods:
- Utilized HaCaT keratinocytes as a model for hyperproliferative epidermis.
- Assessed cellular phosphotyrosine levels after treatment with cyclosporin A, FK506, and dithranol.
- Investigated drug effects in combination with a selective PKC inhibitor (Ro 31-8220).
Main Results:
- Cyclosporin A showed no significant effect on tyrosine phosphorylation.
- FK506 and dithranol markedly reduced tyrosine phosphorylation in HaCaT keratinocytes.
- Inhibition of PKC partially reversed the FK506-induced reduction in phosphotyrosine, but not to baseline levels.
Conclusions:
- FK506 and dithranol decrease tyrosine phosphorylation in keratinocytes, suggesting a mechanism for their therapeutic effect in psoriasis.
- PKC activation alone is not solely responsible for the observed reduction in phosphotyrosine levels.
- Further research is needed to fully elucidate the pathways involved in drug-induced modulation of PTK activity in psoriasis.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway

